Search

Your search keyword '"Nomelini RS"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Nomelini RS" Remove constraint Author: "Nomelini RS"
70 results on '"Nomelini RS"'

Search Results

3. Intramuscular adipose tissue, muscle area, and power as predictors of performance in breast cancer survivors.

4. Resistance Training-Induced Gains in Muscle Strength and Power Mediate the Improvement in Walking Speed in Middle-Aged Women Who Are Breast Cancer Survivors.

5. Immunostaining of stromal CD56 cells in ovarian malignancies.

6. Lower-Body Resistance Training Reduces Interleukin-1β and Transforming Growth Factor-β1 Levels and Fatigue and Increases Physical Performance in Breast Cancer Survivors.

7. Absolute band neutrophils count is a predictor of overall survival in advanced uterine cervical cancer.

8. Mast cells and M2 macrophages in ovarian cancer.

9. CIN Extension at Colposcopy: Relation to Treatment and Blood Parameters.

11. Association of lesion area measured by colposcopy and cervical neoplasia.

12. Association of laboratorial parameters and prognostic factors in uterine corpus cancer.

13. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms.

14. Endometriosis: What is the Influence of Immune Cells?

15. Laboratory parameters as predictors of prognosis in uterine cervical neoplasia.

16. IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas.

17. Improvements in muscle strength, power, and size and self-reported fatigue as mediators of the effect of resistance exercise on physical performance breast cancer survivor women: a randomized controlled trial.

18. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms.

19. Body Mass Index, waist circumference or sagittal abdominal diameter: Which parameter is better correlated with body fat changes in postmenopausal women after combined training protocol?

20. IL-6 and IL-8 as Prognostic Factors in Peritoneal Fluid of Ovarian Cancer.

21. Lymphocytes in Peritumoral Stroma: Evaluation in Epithelial Ovarian Neoplasms.

22. The Role of Stroma in Ovarian Cancer.

23. Laboratory predictors of survival in ovarian cancer.

24. Comparative effects of high-intensity interval training with combined training on physical function markers in obese postmenopausal women: a randomized controlled trial.

25. Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies.

26. Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer.

27. Chemotherapy for cervical cancer in pregnancy.

28. TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.

30. Stromal Growth Differentiation Factor 15 and Its Association with Ovarian Cancer.

31. Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.

32. Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents?

33. Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms.

34. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer.

35. Predicting Functional Capacity From Measures of Muscle Mass in Postmenopausal Women.

36. Parameters of blood count and tumor markers: a retrospective analysis and relation to prognostic factors in ovarian cancer.

37. Gastric and jejunal histopathological changes in patients undergoing bariatric surgery.

38. Abdominopelvic Tuberculosis with a Frozen Section Analysis Consistent with Ovarian Cancer.

39. Cytokines and Prognostic Factors in Epithelial Ovarian Cancer.

40. GASTRIC AND JEJUNAL HISTOPATHOLOGICAL CHANGES IN PATIENTS UNDERGOING BARIATRIC SURGERY.

41. Interleukin-12 in patients with cancer is synthesized by peripheral helper T lymphocytes.

42. Helper T lymphocyte response in the peripheral blood of patients with intraepithelial neoplasia submitted to immunotherapy with pegylated interferon-α.

43. Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

44. Endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors.

46. Correlation of cytokines and inducible nitric oxide synthase expression with prognostic factors in ovarian cancer.

47. The immune response in malignant ovarian neoplasms.

48. Serous papillary cystadenocarcinoma in supernumerary ovary.

49. Conservative treatment of uterine cervical adenocarcinoma in pregnancy.

50. Frequency of endometriosis and adenomyosis in patients with leiomyomas, gynecologic premalignant, and malignant neoplasias.

Catalog

Books, media, physical & digital resources